June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
In-silico comparison of CB2 selectivity among endocannabinoid ω-6 and -3 epoxyethanolamides
Author Affiliations & Notes
  • Minjae James Kim
    Ophthalmology and Visual Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, United States
  • Gary W. McCollum
    Ophthalmology and Visual Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, United States
  • John S Penn
    Ophthalmology and Visual Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, United States
  • Footnotes
    Commercial Relationships   Minjae Kim, None; Gary McCollum, None; John Penn, None
  • Footnotes
    Support  NH Grant EY007533, NH Grant EY023397, VVRC T32 EY007135
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 3017. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Minjae James Kim, Gary W. McCollum, John S Penn; In-silico comparison of CB2 selectivity among endocannabinoid ω-6 and -3 epoxyethanolamides. Invest. Ophthalmol. Vis. Sci. 2021;62(8):3017.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Cannabinoid (CB) receptors are G-coupled protein receptors, and two CB receptors have been identified so far, CB1 and CB2. There is abundant data suggesting that epoxyeicosatrienoic ethanolamides (EET-EAs) and epoxydocosahexaenoic ethanolamides (EDP-EAs), which are derived from ω-6 and -3 fatty acids, respectively, may inhibit retinal inflammation through CB2 activation. In this study, we aim to provide a comprehensive in-silico comparison of the regioisomers of EET-EA and EDP-EA on their affinities to CB1 and CB2.

Methods : CB1 (PDB:5TGZ) and CB2 (PDB:5ZTY) have been used for molecular docking of 5,6-, 8,9-, 11,12-, and 14,15-EET-EA as well as 4,5-, 7,8-, 10,11-, 13,14-, 16,17-, and 19,20-EDP-EA. Additionally, arachidonoyl ethanolamide (AEA), docosahexaenoyl ethanolamide (DHA-EA), CB1-selective AM-6538 (PubChem CID: 46912833), and CB2-selective AM-10257 (PubChem CID: 137321161) have also been investigated. Docking was carried out with AutoDock Vina (Scripps Research, USA) and scored by their binding free energy, ΔG in kcal/mol. Their protein-ligand interactions were visualized with PyMOL (Schrödinger, Inc., USA).

Results : AM-6538 and AM-10257 displayed CB1- and CB2-selectivity, respectively, and their predicted binding modes were consistent with their crystallographies in the literature. AEA and DHA-EA displayed preference for CB2 over CB1, and their metabolites, EET-EA and EDP-EA, shared a similar pattern but showed more CB2-selectivity. This is consistent with the literature in that the epoxygenation step of AEA and DHA-EA serves as a “bioactivation” event, since the products exhibit enhanced selectivity for CB2. Among EET-EAs, 11,12-EET-EA had the highest affinity to CB2 (ΔG of -8.3 kcal/mol). Among EDP-EAs, 19,20-EDP-EA had the highest affinity to CB2 (ΔG of -9.0 kcal/mol). The PyMOL visualization predicted that the intracellular region of CB receptors most likely contains the binding site, where phenylalanine at position 183 in CB2 associates with hydrophobic tails of EET-EA and EDP-EA.

Conclusions : The results predict that EET-EA and EDP-EA bind to the intracellular region of cannabinoid receptors and are more CB2-selective than their parent compounds, AEA and DHA-EA. Considering the rising interest in CB2 agonism to inhibit retinal inflammation, these epoxygenated fatty acids, specifically 11,12-EET-EA and 19,20-EDP-EA, can be potentially useful in inhibiting inflammation in DR.

This is a 2021 ARVO Annual Meeting abstract.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×